Searchable text section of graphics shown above
This Presentation:
This presentation may contain “forward-looking statements” under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.) Statements herein that are not historical facts are forward-looking statements pursuant to the safe harbor provisions referenced above. You may also identify forward-looking statements by use of the words “anticipates,” “expects,” “intends,” “plans” and similar expressions. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified. Such risks and uncertainties include, without limitation the Company���s ability to continue or maintain the improvement in the revenues and margins of its blood products or blood services segment; its ability to continue to control general and administrative expenses as a percent of sales; the need to successfully complete its operating plan to improve profits; the potential loss of the Company’s lines of credit; the potential inability of the Company to meet future capital needs; changing demand for blood products could affect profitability; market prices might not rise as costs increase; competition may cause a loss of customers and an increase in costs; operations depend on obtaining the services of qualified medical professionals and competition for their services is strong; declining blood donations; the Company’s dependence on reimbursement rates of third party providers; targeted partner blood drives involve higher collection costs; reliance on relatively few vendors for significant supplies and services could affect the Company’s ability to operate; limited access to insurance; the competitive advantage enjoyed by not-for-profit companies; potential changes in the healthcare industry; future technology for blood collection and blood replacement; the impact of heavy regulation in the Company’s industry; potential liability for undetected blood pathogens and other product safety and liability concerns; environmental risks associated with biohazardous substances; the threat of business interruption due to terrorism and the security measures taken in response to terrorism; the provisions of the Company’s charter documents that might delay or prevent an acquisition or sale of the Company; lack of liquidity and market risk associated with OTC Bulletin Board stocks; volatility in stock price; potential dilution that could result from future sales of the Company’s common stock; and the other risks and uncertainties discussed from time to time in the documents HemaCare files with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlined in the forward-looking statements contained herein. The Company undertakes no obligation to update any of these forward-looking statements to reflect actual results or events or circumstances after the date hereof.
[LOGO]
2
2005 Financial Highlights
Delivered the highest levels of revenue and pretax income in the 28 year history of the Company
Revenue Growth
[CHART]
Income from Operations Growth
[CHART]
3
Business Development
Revenues from products grew 27% due to expansion of the customer base and growth of sales to existing customers.
Blood Products Revenue
[CHART]
Growth has been focused on higher margin product lines
5
2005 Balance Sheet
Strengthened the Balance Sheet through the growth of Cash and reduction of Debt
Cash in Bank
[CHART]
Capital Leases / Notes Payable
[CHART]
These improvements provide funding for deferred infrastructure investments
7
Infrastructure Investments
• IT Projects
• Document Control
• Financial
• Blood Bank System
• New California Location
• Equipment and Vehicles
8
Financial Performance
• Ten consecutive profitable quarters
• Cash increased
• Debt decreased
• Increased working capital
• Renegotiated LOC
9
Increased Shareholder Value
Stock Value and Market Cap
From the end of 2002 through May 23, 2006, HemaCare stock value has experienced steady growth.
[CHART]
|
| December, 2002 |
| May 23, 2006 |
| ||
Shares Outstanding (approximate) |
| 7,673,000 |
| 8,196,000 |
| ||
Share Price |
| $ | .32 |
| $ | 2.33 |
|
Market Cap |
| $ | 2.5M |
| $ | 19.1M |
|
10
• Joshua Levy, MD, National Medical Director, Founder
• Robert Chilton, CPA, Executive Vice President & CFO
• Annabelle Baltierra, Director of Human Resources
• Ann Coviello, Director of Operations, California
• Gaytha McPherson, National Director of Regulatory Affairs & Quality Assurance
12
• Keith McWilliams, Chief Information Officer
• Jaime Oblitas, Director of Operations, New England
• Rose Shaw, RN, Regional Director of Therapeutics
• Anna Stock, Director of California Fixed Site Operations
• Qing Zhu, RN, Director of Therapeutics
13
Board of Directors
|
| Joined Board |
| |
• Jay Steffenhagen, Chairman |
| 1997 |
| |
• Judi Irving |
| 2002 |
| |
• Steven Gerber, MD |
| 2003 |
| |
• Teresa Sligh, MD |
| 2006 |
| |
• Terry Van Der Tuuk |
| 2003 |
| |
*** |
|
|
|
|
• Robert Johnson, Former Director |
| 1999 - 2006 |
| |
14
Building Our Foundation
2003-2005
• Transition from paid to volunteer donors
• Platelet collections now exceed 2002 levels
15
Path Forward
• Profitably grow blood products and services
• Invest in infrastructure
• Develop Research opportunities
19